BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lentzsch S, Chatterjee M, Gries M, Bommert K, Gollasch H, Dörken B, Bargou RC. PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells. Leukemia 2004;18:1883-90. [PMID: 15356648 DOI: 10.1038/sj.leu.2403486] [Cited by in Crossref: 84] [Cited by in F6Publishing: 69] [Article Influence: 4.9] [Reference Citation Analysis]
Number Citing Articles
1 John L, Krauth MT, Podar K, Raab MS. Pathway-Directed Therapy in Multiple Myeloma. Cancers (Basel) 2021;13:1668. [PMID: 33916289 DOI: 10.3390/cancers13071668] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chatterjee M, Jain S, Stuhmer T, Andrulis M, Ungethum U, Kuban RJ, Lorentz H, Bommert K, Topp M, Kramer D. STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood. 2007;109:720-728. [PMID: 17003370 DOI: 10.1182/blood-2006-05-024372] [Cited by in Crossref: 106] [Cited by in F6Publishing: 104] [Article Influence: 7.1] [Reference Citation Analysis]
3 Yudoh K, Shi Y, Karasawa R. Angiogenic growth factors inhibit chondrocyte ageing in osteoarthritis: potential involvement of catabolic stress-induced overexpression of caveolin-1 in cellular ageing. Int J Rheum Dis 2009;12:90-9. [PMID: 20374325 DOI: 10.1111/j.1756-185X.2009.01390.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Smolewski P. Investigating mammalian target of rapamycin inhibitors for their anticancer properties. Expert Opinion on Investigational Drugs 2006;15:1201-27. [DOI: 10.1517/13543784.15.10.1201] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
5 Smolewski P. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006;17:487-94. [PMID: 16702804 DOI: 10.1097/00001813-200606000-00001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 5.3] [Reference Citation Analysis]
6 Chatterjee M, Stühmer T, Herrmann P, Bommert K, Dörken B, Bargou RC. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004;104:3712-21. [PMID: 15297310 DOI: 10.1182/blood-2004-04-1670] [Cited by in Crossref: 95] [Cited by in F6Publishing: 96] [Article Influence: 5.6] [Reference Citation Analysis]
7 Rowe DD, Leonardo CC, Recio JA, Collier LA, Willing AE, Pennypacker KR. Human umbilical cord blood cells protect oligodendrocytes from brain ischemia through Akt signal transduction. J Biol Chem 2012;287:4177-87. [PMID: 22158864 DOI: 10.1074/jbc.M111.296434] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
8 Hori YS, Aoi M, Oda K, Fukuhara T. Presence of a Malignant Tumor as a Novel Predictive Factor for Repeated Recurrences of Chronic Subdural Hematoma. World Neurosurgery 2017;105:714-9. [DOI: 10.1016/j.wneu.2017.06.043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
9 Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 2010;115:3939-48. [PMID: 20190189 DOI: 10.1182/blood-2009-10-251660] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 7.3] [Reference Citation Analysis]
10 Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opinion on Therapeutic Targets 2013;17:1303-28. [DOI: 10.1517/14728222.2013.830105] [Cited by in Crossref: 39] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
11 Yiau SK, Lee C, Mohd Tohit ER, Chang KM, Abdullah M. Potential CD34 signaling through phosphorylated-BAD in chemotherapy-resistant acute myeloid leukemia. J Recept Signal Transduct Res 2019;39:276-82. [PMID: 31509041 DOI: 10.1080/10799893.2019.1660899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Chen J, Huang X. Interleukin-6 Promotes Carcinogenesis Through Multiple Signal Pathways: Comment on: Clinical Significance of Interleukin-6 Gene Polymorphism and IL-6 Serum Level in Pancreatic Adenocarcinoma and Chronic Pancreatitis. Dig Dis Sci 2009;54:1373-4. [DOI: 10.1007/s10620-009-0794-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
13 Sikka S, Shanmugam MK, Kannaiyan R, Surana R, Shin EM, Kumar AP, Sethi G, Ahn KS. Suppression of essential pro-inflammatory signaling pathways by natural agents for the therapy of Multiple Myeloma. Phytochem Rev 2014;13:79-106. [DOI: 10.1007/s11101-013-9287-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Kardosh A, Soriano N, Liu Y, Uddin J, Petasis NA, Hofman FM, Chen TC, Schönthal AH. Multitarget inhibition of drug-resistant multiple myeloma cell lines by dimethyl-celecoxib (DMC), a non–COX-2 inhibitory analog of celecoxib. Blood 2005;106:4330-8. [DOI: 10.1182/blood-2005-07-2819] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 2.8] [Reference Citation Analysis]
15 Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-hermelink H, Andrulis M, Greiner A, Wesemeier C, Rath JC, Einsele H, Bargou RC. Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 2008;112:3403-11. [DOI: 10.1182/blood-2007-11-119362] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
16 Tiacci E, Liso A, Piris M, Falini B. Evolving concepts in the pathogenesis of hairy-cell leukaemia. Nat Rev Cancer 2006;6:437-48. [DOI: 10.1038/nrc1888] [Cited by in Crossref: 69] [Cited by in F6Publishing: 55] [Article Influence: 4.6] [Reference Citation Analysis]
17 Ramakrishnan V, D'Souza A. Signaling Pathways and Emerging Therapies in Multiple Myeloma. Curr Hematol Malig Rep 2016;11:156-64. [PMID: 26922744 DOI: 10.1007/s11899-016-0315-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
18 Glauer J, Pletz N, Schön M, Schneider P, Liu N, Ziegelbauer K, Emmert S, Wulf GG, Schön MP. A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo. Blood Cancer J 2013;3:e141. [PMID: 24013662 DOI: 10.1038/bcj.2013.37] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
19 Qiong Z, Ruofan H, Xiaohua L, Xinli Z, Jingwei J, Zhaohui C. Role of dephosphorylation of FOXO1 on apoptosis induced by wortmannin for non-Hodgkin’s lymphoma cells. Mol Biol Rep 2010;37:2397-402. [DOI: 10.1007/s11033-009-9748-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
20 Schmidt-Hieber M, Dabrowski R, Weimann A, Aicher B, Lohneis P, Busse A, Thiel E, Blau IW. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines. Invest New Drugs 2012;30:480-9. [PMID: 21080211 DOI: 10.1007/s10637-010-9576-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
21 Trotter TN, Gibson JT, Sherpa TL, Gowda PS, Peker D, Yang Y. Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone. Am J Pathol 2016;186:3054-63. [PMID: 27648615 DOI: 10.1016/j.ajpath.2016.07.012] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 7.6] [Reference Citation Analysis]
22 Wang Y, Li L, Guo X, Jin X, Sun W, Zhang X, Xu RC. Interleukin-6 signaling regulates anchorage-independent growth, proliferation, adhesion and invasion in human ovarian cancer cells. Cytokine 2012;59:228-36. [PMID: 22595649 DOI: 10.1016/j.cyto.2012.04.020] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 7.1] [Reference Citation Analysis]
23 Chang-Yew Leow C, Gerondakis S, Spencer A. MEK inhibitors as a chemotherapeutic intervention in multiple myeloma. Blood Cancer J 2013;3:e105. [PMID: 23524590 DOI: 10.1038/bcj.2013.1] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
24 Karadedou CT, Gomes AR, Chen J, Petkovic M, Ho KK, Zwolinska AK, Feltes A, Wong SY, Chan KY, Cheung YN, Tsang JW, Brosens JJ, Khoo US, Lam EW. FOXO3a represses VEGF expression through FOXM1-dependent and -independent mechanisms in breast cancer. Oncogene 2012;31:1845-58. [PMID: 21860419 DOI: 10.1038/onc.2011.368] [Cited by in Crossref: 100] [Cited by in F6Publishing: 98] [Article Influence: 10.0] [Reference Citation Analysis]
25 Ruan M, Pederson L, Bradley EW, Bamberger AM, Oursler MJ. Transforming growth factor-{beta} coordinately induces suppressor of cytokine signaling 3 and leukemia inhibitory factor to suppress osteoclast apoptosis. Endocrinology 2010;151:1713-22. [PMID: 20181800 DOI: 10.1210/en.2009-0813] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
26 Pinto V, Bergantim R, Caires HR, Seca H, Guimarães JE, Vasconcelos MH. Multiple Myeloma: Available Therapies and Causes of Drug Resistance. Cancers (Basel) 2020;12:E407. [PMID: 32050631 DOI: 10.3390/cancers12020407] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 42.0] [Reference Citation Analysis]
27 Hirano M, Imai Y, Kaito Y, Murayama T, Sato K, Ishida T, Yamamoto J, Ito T, Futami M, Ri M, Yasui H, Denda T, Tanaka Y, Ota Y, Nojima M, Kamikubo Y, Gotoh N, Iida S, Handa H, Tojo A. Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma. J Exp Clin Cancer Res 2021;40:110. [PMID: 33757580 DOI: 10.1186/s13046-021-01909-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Lishner M, Zismanov V, Tohami T, Tartakover-Matalon S, Elis A, Drucker L. Tetraspanins affect myeloma cell fate via Akt signaling and FoxO activation. Cell Signal 2008;20:2309-16. [PMID: 18804164 DOI: 10.1016/j.cellsig.2008.08.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
29 Yang J, Zhang X, Wang J, Qian J, Zhang L, Wang M, Kwak LW, Yi Q. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 2007;110:3028-35. [PMID: 17644731 DOI: 10.1182/blood-2007-06-094417] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 2.7] [Reference Citation Analysis]
30 Tsubaki M, Takeda T, Tomonari Y, Mashimo K, Koumoto YI, Hoshida S, Itoh T, Imano M, Satou T, Sakaguchi K, Nishida S. The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs. J Cell Physiol 2018;233:4258-71. [PMID: 29057477 DOI: 10.1002/jcp.26245] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
31 Leung KN, Mak NK, Fung MC. Cytokines in the differentiation therapy of leukemia: from laboratory investigations to clinical applications. Crit Rev Clin Lab Sci 2005;42:473-514. [PMID: 16390682 DOI: 10.1080/10408360500295154] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
32 Feng R, Anderson G, Xiao G, Elliott G, Leoni L, Mapara MY, Roodman GD, Lentzsch S. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth. Blood 2007;109:2130-8. [PMID: 17095620 DOI: 10.1182/blood-2006-07-027458] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
33 Liu Q, Alinari L, Chen CS, Yan F, Dalton JT, Lapalombella R, Zhang X, Mani R, Lin T, Byrd JC, Baiocchi RA, Muthusamy N. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma. Clin Cancer Res 2010;16:3182-92. [PMID: 20460491 DOI: 10.1158/1078-0432.CCR-09-2484] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
34 Meng Q, Roubin RH, Hanrahan JR. Ethnopharmacological and bioactivity guided investigation of five TCM anticancer herbs. Journal of Ethnopharmacology 2013;148:229-38. [DOI: 10.1016/j.jep.2013.04.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
35 Li QF, Zhu HY, Yang YF, Liu J, Xiao FJ, Zhang QW, Wu CT, Wang H, Wang LS. Prokineticin-1/endocrine gland-derived vascular endothelial growth factor is a survival factor for human multiple myeloma cells. Leuk Lymphoma 2010;51:1902-12. [PMID: 20795791 DOI: 10.3109/10428194.2010.512963] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
36 Attar-Schneider O, Drucker L, Zismanov V, Tartakover-Matalon S, Rashid G, Lishner M. Bevacizumab attenuates major signaling cascades and eIF4E translation initiation factor in multiple myeloma cells. Lab Invest 2012;92:178-90. [PMID: 22083671 DOI: 10.1038/labinvest.2011.162] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
37 Masih-Khan E, Trudel S, Heise C, Li Z, Paterson J, Nadeem V, Wei E, Roodman D, Claudio JO, Bergsagel PL, Stewart AK. MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood 2006;108:3465-71. [PMID: 16849642 DOI: 10.1182/blood-2006-04-017087] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 3.9] [Reference Citation Analysis]
38 Abramson HN. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. Int J Mol Sci 2020;21:E5192. [PMID: 32707894 DOI: 10.3390/ijms21155192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
39 Fu R, Liu H, Zhao S, Wang Y, Li L, Gao S, Ruan E, Wang G, Wang H, Song J, Shao Z. Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell Int 2014;14:132. [PMID: 25520585 DOI: 10.1186/s12935-014-0132-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
40 Bommert K, Bargou RC, Stühmer T. Signalling and survival pathways in multiple myeloma. Eur J Cancer 2006;42:1574-80. [PMID: 16797970 DOI: 10.1016/j.ejca.2005.12.026] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 7.5] [Reference Citation Analysis]
41 Gangavarapu KJ, Olbertz JL, Bhushan A, Lai JC, Daniels CK. Apoptotic resistance exhibited by dexamethasone-resistant murine 7TD1 cells is controlled independently of interleukin-6 triggered signaling. Apoptosis 2008;13:1394-400. [PMID: 18819004 DOI: 10.1007/s10495-008-0265-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
42 Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006;107:4053-4062. [PMID: 16418332 DOI: 10.1182/blood-2005-08-3434] [Cited by in Crossref: 312] [Cited by in F6Publishing: 288] [Article Influence: 20.8] [Reference Citation Analysis]
43 Waizenegger JS, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab MS, Pantel K, Bokemeyer C, Loges S. Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma. Leukemia 2015;29:696-704. [PMID: 25102945 DOI: 10.1038/leu.2014.236] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
44 Leich E, Weißbach S, Klein HU, Grieb T, Pischimarov J, Stühmer T, Chatterjee M, Steinbrunn T, Langer C, Eilers M, Knop S, Einsele H, Bargou R, Rosenwald A. Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules. Blood Cancer J 2013;3:e102. [PMID: 23396385 DOI: 10.1038/bcj.2012.47] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
45 Liu S, Ma Z, Cai H, Li Q, Rong W, Kawano M. Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells. Eur J Haematol. 2010;84:137-144. [PMID: 19878271 DOI: 10.1111/j.1600-0609.2009.01365.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
46 Glund S, Krook A. Role of interleukin-6 signalling in glucose and lipid metabolism: IL-6 and glucose and lipid metabolism. Acta Physiologica 2008;192:37-48. [DOI: 10.1111/j.1748-1716.2007.01779.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 5.6] [Reference Citation Analysis]
47 Ntellas P, Mavroeidis L, Gkoura S, Gazouli I, Amylidi AL, Papadaki A, Zarkavelis G, Mauri D, Karpathiou G, Kolettas E, Batistatou A, Pentheroudakis G. Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer. Cancers (Basel) 2020;12:E3145. [PMID: 33121034 DOI: 10.3390/cancers12113145] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
48 Soria G, Ben-baruch A. The CCL5/CCR5 Axis in Cancer. In: Fulton AM, editor. Chemokine Receptors in Cancer. Totowa: Humana Press; 2009. pp. 109-30. [DOI: 10.1007/978-1-60327-267-4_7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
49 Mundra JJ, Terskiy A, Howells RD. Naltrindole inhibits human multiple myeloma cell proliferation in vitro and in a murine xenograft model in vivo. J Pharmacol Exp Ther 2012;342:273-87. [PMID: 22537770 DOI: 10.1124/jpet.112.194159] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
50 Shankar S, Srivastava RK. Curcumin: Structure, Biology and Clinical Applications. In: Shankar S, Srivastava RK, editors. Nutrition, Diet and Cancer. Dordrecht: Springer Netherlands; 2012. pp. 413-57. [DOI: 10.1007/978-94-007-2923-0_17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
51 Ramakrishnan VG, Miller KC, Macon EP, Kimlinger TK, Haug J, Kumar S, Gonsalves WI, Rajkumar SV, Kumar SK. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma. Haematologica 2019;104:2061-74. [PMID: 30846494 DOI: 10.3324/haematol.2018.211110] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
52 Lentzsch S. Death by rafting. Blood 2007;110:2791-2. [DOI: 10.1182/blood-2007-08-105510] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Kurdi M, Booz GW. Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling. J Cardiovasc Pharmacol 2007;50:126-41. [PMID: 17703129 DOI: 10.1097/FJC.0b013e318068dd49] [Cited by in Crossref: 55] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
54 Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 2007;138:783-91. [PMID: 17760810 DOI: 10.1111/j.1365-2141.2007.06714.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 5.8] [Reference Citation Analysis]
55 Kim SY, Yoon J, Ko YS, Chang MS, Park JW, Lee HE, Kim MA, Kim JH, Kim WH, Lee BL. Constitutive phosphorylation of the FOXO1 transcription factor in gastric cancer cells correlates with microvessel area and the expressions of angiogenesis-related molecules. BMC Cancer. 2011;11:264. [PMID: 21696576 DOI: 10.1186/1471-2407-11-264] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 3.3] [Reference Citation Analysis]
56 Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007;20:597-612. [PMID: 18070708 DOI: 10.1016/j.beha.2007.08.002] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
57 Desai S, Kumar A, Laskar S, Pandey BN. Differential roles of ATF-2 in survival and DNA repair contributing to radioresistance induced by autocrine soluble factors in A549 lung cancer cells. Cell Signal 2014;26:2424-35. [PMID: 25041846 DOI: 10.1016/j.cellsig.2014.07.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
58 Hattori N, Nakamaki T, Ariizumi H, Homma M, Yamochi-Onizuka T, Ota H, Tomoyasu S. Over-expression of CCL3 MIP-1alpha in a blastoid mantle cell lymphoma with hypercalcemia. Eur J Haematol 2010;84:448-52. [PMID: 20050882 DOI: 10.1111/j.1600-0609.2009.01405.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
59 de Gorter DJ, Reijmers RM, Beuling EA, Naber HP, Kuil A, Kersten MJ, Pals ST, Spaargaren M. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood 2008;111:3364-72. [PMID: 18227351 DOI: 10.1182/blood-2007-08-106583] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
60 Kim JH, Kim MK, Lee HE, Cho SJ, Cho YJ, Lee BL, Lee HS, Nam SY, Lee JS, Kim WH. Constitutive phosphorylation of the FOXO1A transcription factor as a prognostic variable in gastric cancer. Mod Pathol 2007;20:835-42. [PMID: 17491598 DOI: 10.1038/modpathol.3800789] [Cited by in Crossref: 30] [Cited by in F6Publishing: 36] [Article Influence: 2.1] [Reference Citation Analysis]
61 Burger R, Günther A, Klausz K, Staudinger M, Peipp M, Penas EM, Rose-John S, Wijdenes J, Gramatzki M. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica 2017;102:381-90. [PMID: 27658435 DOI: 10.3324/haematol.2016.145060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
62 Bloedjes TA, de Wilde G, Maas C, Eldering E, Bende RJ, van Noesel CJM, Pals ST, Spaargaren M, Guikema JEJ. AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. Blood Adv 2020;4:4151-64. [PMID: 32898245 DOI: 10.1182/bloodadvances.2019001393] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
63 Chatterjee M, Rancso C, Stühmer T, Eckstein N, Andrulis M, Gerecke C, Lorentz H, Royer HD, Bargou RC. The Y-box binding protein YB-1 is associated with progressive disease and mediates survival and drug resistance in multiple myeloma. Blood 2008;111:3714-22. [PMID: 18006704 DOI: 10.1182/blood-2007-05-089151] [Cited by in Crossref: 73] [Cited by in F6Publishing: 69] [Article Influence: 5.2] [Reference Citation Analysis]
64 Roodman GD. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev 2012;31:569-78. [PMID: 22706844 DOI: 10.1007/s10555-012-9372-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
65 Liu T, Fei Z, Gangavarapu KJ, Agbenowu S, Bhushan A, Lai JC, Daniels CK, Cao S. Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells. Leuk Res 2013;37:1322-8. [PMID: 23871159 DOI: 10.1016/j.leukres.2013.06.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
66 van de Donk NWCJ, Lokhorst HM, Bloem AC. Growth factors and antiapoptotic signaling pathways in multiple myeloma. Leukemia 2005;19:2177-85. [DOI: 10.1038/sj.leu.2403970] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
67 Paesler J, Gehrke I, Poll-wolbeck SJ, Kreuzer K. Targeting the vascular endothelial growth factor in hematologic malignancies. Eur J Haematol 2012;89:373-84. [DOI: 10.1111/ejh.12009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
68 Quinlan MP, Quatela SE, Philips MR, Settleman J. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol Cell Biol. 2008;28:2659-2674. [PMID: 18268007 DOI: 10.1128/mcb.01661-07] [Cited by in Crossref: 59] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
69 Keane NA, Glavey SV, Krawczyk J, O'Dwyer M. AKT as a therapeutic target in multiple myeloma. Expert Opin Ther Targets 2014;18:897-915. [PMID: 24905897 DOI: 10.1517/14728222.2014.924507] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]